Microbiome effects on immunity, health and disease in the lung

Shakti D Shukla, Kurtis F Budden, Rachael Neal and Philip M Hansbro

Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), are among the leading causes of mortality and morbidity worldwide. In the past decade, the interest in the role of microbiome in maintaining lung health and in respiratory diseases has grown exponentially. The advent of sophisticated multimics techniques has enabled the identification and characterisation of microbiota and their roles in respiratory health and disease. Furthermore, associations between the microbiome of the lung and gut, as well as the immune cells and mediators that may link these two mucosal sites, appear to be important in the pathogenesis of lung conditions. Here we review the recent evidence of the role of normal gastrointestinal and respiratory microbiome in health and how dysbiosis affects chronic pulmonary diseases. The potential implications of host and environmental factors such as age, gender, diet and use of antibiotics on the composition and overall functionality of microbiome are also discussed. We summarise how microbiota may mediate the dynamic process of immune development and/or regulation focusing on recent data from both clinical human studies and translational animal studies. This furthers the understanding of the pathogenesis of chronic pulmonary diseases and may yield novel avenues for the utilisation of microbiota as potential therapeutic interventions.

Clinical & Translational Immunology (2017) 6, e133; doi:10.1038/cti.2017.6; published online 10 March 2017

CHRONIC RESPIRATORY DISEASES

Chronic respiratory diseases, namely asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), are among the leading cause of morbidity and mortality worldwide. In Australia, deaths due to respiratory disease are among top five causes of mortality, and COPD alone is the second most common cause of hospitalisation. Mortality rates are expected to rise significantly in the next decade, partly due to ageing populations and also as a result of the lack of effective measures to reduce some of the major risk factors such as smoking, air pollution, wood and cooking smoke. There are also likely to be generational effects of exposures prolonging these effects into subsequent generations even if exposures were to decline now. Despite the enormous burden of these conditions, the various causative factors and underlying mechanisms associated with disease progression are still not fully understood. The human microbiome is one such factor, which not only has a pivotal role in maintaining health but also in regulating various inflammatory and metabolic pathways in a range of conditions including gastrointestinal (GI) diseases (inflammatory bowel disease, irritable bowel syndrome), arthritis (rheumatoid arthritis), cancer (colorectal cancer) and recently in chronic pulmonary diseases, such as asthma, COPD and CF.

Early investigations largely focussed on the roles of intestinal commensal bacteria and their metabolites in health and disease. However, new evidence suggests that non-bacterial microorganisms such as fungi (mycobiome) and viruses (virome), as well as microbiota residing on other tissues such as the lungs, could be critical in modulating health and disease in the host. The term ‘microbiota’ refers to the entire microbial community (bacteria, archaea, fungi, viruses and protozoa) associated with specific host tissues or organs, whereas the total genome of this community is designated the ‘microbiome’. Accordingly, the human microbiome can be defined as the sum total of all forms of microorganisms and their genomes, inhabiting an individual, at a given time. The composition and diversity of microbiota varies greatly between different individuals and is shaped by both environmental and host genetics factors, although it remains relatively stable within a host in the absence of a major change in lifestyle (e.g., diet, disease onset, inhalation and environment exposures etc.). Remarkably, the microbiome is often dubbed the ‘new’ biomarker of human health as it aids in maintaining normal host physiology, developing and educating the immune system, metabolising complex substrates and providing crucial protection against opportunistic pathogens. With the rapid technological advances in the field of metagenomics and bioinformatics, researchers are now unravelling the effects of both the respiratory and GI microbiota on the immunity of lungs in health and disease.

Here we review the relationships between the host and the microbiota in chronic respiratory disorders (e.g., asthma, COPD and CF), and outline novel microbiome-oriented strategies with therapeutic potential for preventing or treating these diseases, which are currently incurable and often have poor treatment options.
HEALTHY MICROBIOME IN THE GI AND RESPIRATORY TRACTS

The comprehensive analysis of microbial communities, the implication of individual taxa in biological processes and the identification of interactions between the microbiota, host and the immune response have been driven by the development and application of new technologies and advanced high-throughput bioinformatics techniques. Although a detailed discussion of modern sequencing and analysis would form its own review, familiarity with the basic principles is key to understanding the workflow and potential limitations in the field. The DNA encoding the 16S rRNA gene is amplifiable by PCR, and consists of both conserved regions present in all prokaryotes and variable (V1–V9) sequence regions. Notably, these regions have evolved at different rates, allowing measurement of both close and distant phylogenetic relationships, which enables the taxonomic assignment of a broad range of bacteria to family/genus/species level. Similarly, fungal detection by DNA based technologies include sequencing and evaluation of conserved 18S rRNA gene (phyllum level differentiation), which can be coupled with highly variable internal transcribed spacer regions (ITS) to achieve interspecies separation. It should be noted that the utility of 18S rRNA/ITS sequencing based approaches for fungal identification can be confounded by the specificity and bias of currently available PCR primers, as well as the lack of exhaustive fungal reference libraries. Despite some concerns about the variability of experimental protocols or PCR primer bias, 16S rRNA/18S rRNA remain the mainstay of microbiome analysis.Briefly, total DNA is extracted from the sample (e.g., stool, bronchoalveolar lavage fluid, tissue) and the bacterial 16S rRNA gene is PCR-amplified to create a mix of individual amplicons. For eukaryotic microbes (fungi and protozoa), 18S rRNA/ITS genes are amplified and assessed. Similar phylogenetic characterisation of viruses/phages can be undertaken but is difficult owing to the lack of small subunit rRNA (16S/18S), or any conserved genes/proteins. In addition, overlapping of specific marker genes that are frequently transferred between viruses through horizontal gene transfer induces further challenges for the identification and characterisation of viruses. However, with the advent of next-generation sequencing and sophisticated methods for purifying virus-like particles, it is now possible to assess viral diversity through shotgun sequencing. Then next generation sequencing (NGS) technology is employed to analyse these sequences simultaneously, thus avoiding the pedestrian traditional separation and cloning of individual amplified sequences and reducing the biases. These 16S rRNA gene amplicon sequences are assessed qualitatively and highly similar sequences are clustered into operational taxonomic units (OTUs), which are finally identified against a standard reference database. It may be possible to classify some OTUs to the species level, while others may be classified only to a higher taxonomic level such as family or genus. This is primarily due to the varying resolution in the sequencing reads of specific regions of the 16S rRNA gene used for distinguishing different types of bacteria. The total number of reads assigned to each operational taxonomic unit is indicative of the relative abundance of members of the microbiome, as well as characterising their phylogenetic relationships, that is, taxonomic diversity. These microbial profiles can then be correlated with host physiological parameters in both health and disease. More recently, the advent of whole-genome sequencing and functional metagenomics (i.e., genome-based pathway analyses) has enabled the prediction of the functionality of whole microbial communities as well as of individual members. The sequencing of 16S rRNA gene amplicons of bacteria, and 18S rRNA/ITS gene amplicons of fungi, allows the cost-effective identification and characterisation of microbial diversity in ecosystems, including the human gut. This has proved extremely valuable in enabling the analysis of host-microbe interactions in health and disease. However, several key issues remain to be resolved, such as reducing PCR-bias, accurate projections of microbial diversity, translating microbial taxonomic classification into essential biological parameters, and determining cause and effect of species and population changes. Crucially, shotgun metagenome sequencing provides both the identification of microbes and the information regarding biological function encoded in the total genome. Major challenges still exist with this technique, including analysis of extremely complex data into meaningful conclusions, presence of host DNA in the whole sample, exclusion of sequences generated due to contaminants and high cost. However, both 16S rRNA sequencing and shotgun metagenome sequencing are in use across in many laboratories worldwide, and with advances made in refining these techniques, it will become more sophisticated and affordable in coming years. Additional molecular methods such as metatranscriptomics (analysis of mRNA transcripts), metaproteomics (analysis of proteins) and metabolomics (analysis of metabolites) have also proved beneficial in understanding the functional complexity of host–microbe interactions.

The total surface area of the gastrointestinal mucosa in the adult human is between 30 and 80 m², and this harbours large populations of microorganisms (~10¹⁴), which are predominantly commensal in nature. To characterise the ‘healthy’ microbiome in humans, Qin et al. sequenced the total faecal genetic material from 124 European adults and revealed that the gut microbiota is predominantly comprised of bacteria and archaea, representative of ~1000 distinct species, with less populations of viruses and eukaryotic microbes. These ‘Healthy’ gut microbiota are dominated by the phyla Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria and Verrucomicrobia with a lesser proportion of Fusobacteria. Regional tissue variations in microbiome composition exist in the GI tract, which are determined by factors such as oxygen gradient, antimicrobial peptides (bile acids) and pH. Lactobacillaceae and Enterobacteriaceae dominate small intestine (~10⁵ CFU g⁻¹), whereas the colon (~10¹¹ CFU g⁻¹) is inhabited by members of Bacteroidaceae, Prevotellaceae, Rikenellaceae, Lachnospiraceae and Ruminococcaceae. Consequently, luminal- (faeces) and mucosal-associated (colonic mucosa) microbiota demonstrate the persistence of distinct microbial taxa, differing in both diversity and composition, with luminal populations showing higher diversity. Mouse models are integral to understanding the role of the GI microbiome in immune disorders. Lagrouwardos et al. recently established the first public library of the Mouse Intestinal Bacterial Collection. Approximately 1500 pure cultures were isolated from the GI tract of mice, and 76 different species from 26 families belonging to the phyla Firmicutes (74% strains), Actinobacteria, Bacteroidetes, Proteobacteria and Verrucomicrobia were identified, characterised and archived. The authors also identified 32 bacterial species shared between both humans and mice, and 16 species that were exclusively present in the murine intestine. Other key factors such as variability in the gut microbiome between different laboratory mouse strains and environmental factors (e.g., co-housing, physical/psychological stress) should be considered while referring to miBC library. Moreover, further investigations are warranted to resolve differences in the composition of the gut microbiota in different mouse strains, and the influence of their respective microbiota on health and disease. Recently, our knowledge of the respiratory microbiome has improved significantly. Previously thought to be sterile, numerous investigators have detected bacterial DNA in the lower respiratory tract.
Factors affecting the microbiome

**Early life**
- Maternal BMI
- Pre-term pharmacotherapy (e.g., antibiotics, steroids)
- 0-3 months Caesarean
  - ↓ Actinobacteria
  - ↓ Bacteroidetes
  - ↑ Firmicutes
- 1-3 years Breastfeeding cessation
  - ↑ Bacteroidetes
  - ↑ Firmicutes
- Day care attendance

**Adult life**
- Cigarette smoke
- Allergens
- Infections
- Air pollution
- • Age
  • Gender
  • BMI
  • Onset of chronic diseases
  • Diet (e.g., High fiber vs. high fat)
  • Pharmacotherapy (e.g., antibiotics, steroids)

*Figure 1* Factors affecting microbiome in early life and adulthood. Host microbiome in both early and adult life is affected by various factors. Preterm (during gestation) determinants of microbiome include maternal BMI and pharmacotherapy, whereas post-term factors such as mode of delivery, duration of breastfeeding, day-care attendance and diet (throughout life) significantly influence the microbiome composition. Environmental factors, for example, exposure to cigarette smoke/air pollution/allergens, respiratory infections as well as host-associated factors such as age, gender, BMI and onset of chronic diseases could result in ‘dysbiosis’.

Establishment of the microbiome

The establishment of the microbiome may commence before an individual is born, as nonpathogenic commensal microbes, largely resembling the oral microbiota, have been detected from placental DNA (Figure 1). At birth, the mode of delivery affects early colonisation in the gut, with delivery by caesarean section shown to be significantly associated with lower abundance and diversity of the phyla Actinobacteria and Bacteroidetes, whereas higher abundance and diversity of Firmicutes in the first 3 months of life. Other factors including the place of birth, feeding practice, host genetics, siblings, gender and preterm pharmacotherapy (e.g., antibiotics, steroids) could also affect the microbiome substantially. At age 1–2 years, the infant gut microbiome changes dramatically, although detectable changes in microbiota may occur as early as 6 weeks post birth as these changes are largely shaped by the cessation of breastfeeding and subsequent alterations in diet. During the next 18–36 months, a final shift in microbiota takes place in the majority of individuals, which primarily involves enrichment with bacterial phyla Bacteroidetes and Firmicutes, and leads to a microbiome resembling that of adults. Once established, the microbiome remains fairly stable throughout middle age, with only transient changes occurring. A 5-year follow-up study of US adults showed that the relative abundance of the majority of bacterial strains (~60%), especially Bacteroidetes and Actinobacteria, remain fairly stable in an individual. Nevertheless, there is a large degree of interpersonal variation of microbiota, which is mainly due to host associated factors, including diet, genetics, age and gender (Figure 1) and new taxa continue to be characterised. Data generated by the Human Microbiome Project reported significant correlations between the first principle coordinates of host genetic variations and first principle coordinate of microbiome composition in stool samples and palatine tonsils (UniFrac distances). Similar statistically nonsignificant correlations between host genome and microbiota composition were also observed for other body sites, such as the skin. Another study also used the Human Microbiome Project data to show that mitochondrial haplotypes correlated with abundances of specific microbiota in faeces. Other factors can also lead to long-term sustained changes in the composition of gut microbiota, such as the onset of chronic diseases, changes in diet or repeated exposure to environmental insults, such as cigarette smoke, allergens, infections and air pollution (Figure 1). Gender-specific differences
in microbiota also occur and could possibly explain differences in the prevalence of metabolic and intestinal inflammatory diseases in men compared with women.\textsuperscript{46} Gut bacterial microbiota differs between men and women at the phylum (Firmicutes:Bacteroidetes) ratio higher in men < 33 kg m\(^{-2}\) body mass index (BMI); higher in women > 33 kg m\(^{-2}\) BMI as well as genus level (Bacteroides and \textit{Bilophila} higher in women; \textit{Veillonella} and \textit{Methanobrevibacter} higher in men).\textsuperscript{46} In the same study, levels of 66 bacterial genera strongly correlated with both BMI and plasma lipids (triglycerides, high- and low-density lipoproteins and total cholesterol).\textsuperscript{46} Evidence also suggests that commensal gut microbial communities affect both sex hormone levels and metabolomics in a non-obese mouse model of type 1 diabetes (T1D), and also regulates autoimmune diseases in these genetically susceptible animals.\textsuperscript{47} Furthermore, recent evidence suggests that normal ageing profoundly affects the composition of microbiome, in both humans and mice,\textsuperscript{17,48} and is strongly influenced by BMI (Figure 1).

**Effects of diet and other factors on microbiome composition**

Thomson and co-workers analysed stool samples from nine infants (age: 7 days–10.5 months; followed weekly for 16 weeks) and reported that the infant microbiome was affected by age, diet and day-care attendance. They also found a greater plasticity in microbiome composition in exclusively breastfed infants compared with non-exclusively breastfed infants, although the phylogenetic diversity and species richness was diminished in exclusively breastfed infants.\textsuperscript{49} In 33 children with irritable bowel syndrome, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) was found to be effective in reducing the frequency of abdominal pain, compared with a typical American childhood diet.\textsuperscript{50} Independent of maternal BMI, a maternal high-fat diet was associated with a notable relative depletion of \textit{Bacteroides} in neonates at birth, which persisted up to 6 weeks of age.\textsuperscript{51} In adults, a short-term (5-day) dietary intervention (entire plant or animal based) significantly altered gut microbial community structure (with notable increases in the genus \textit{Prevotella}) and accounted for individual differences in microbiome-associated metabolic gene expression.\textsuperscript{52} Consumption of fibre is also important in maintaining the composition of the microbiome as a low fibre diet has recently been shown to cause an irreversible loss in gut bacterial diversity over several generations in mice.\textsuperscript{53}

Lee and Ko\textsuperscript{54} reported that oral administration of retinoic acid significantly increased the abundance of members of \textit{Lactobacillaceae} families in the murine gut, which inhibited murine noroviral replication in the host through the upregulation of interferon-β. Prebiotic feeding of β(1-4)galacto-oligosaccharides (GOS90) formulation to germ-free (GF) mice colonised with normal mouse gut microbiota resulted in increased abundance of \textit{Bifidobacterium adolescentis} (\textit{B. adolescentis}), \textit{B. pseudocatenulatum}, \textit{B. lactis} and \textit{B. gallicum} and decreased abundance of \textit{Bacteroides}, \textit{Helicobacter} and \textit{Clostridium}. However, the prebiotic diet (GOS90) was not associated with an altered inflammatory profile (interleukin-6 (IL-6), IL-12, IL-1β, interferon-γ and tumour necrosis factor-α).\textsuperscript{55}

Recent evidence also indicates the role of gut microbiota in aggravating metabolic inflammation via toll-like receptor (TLR) signalling (primarily TLR2 and TLR4) induced with a saturated lipid-rich diet. Feeding mice a diet rich in saturated fats resulted in weight gain, higher food consumption and reduced respiratory quotient as well as increased the abundance of genera \textit{Bacteroides}, \textit{Turicibacter} and \textit{Bilophila}. This was in comparison with a diet rich in polyunsaturated lipids in which the genera \textit{Actinobacteria} (\textit{Bifidobacterium} and \textit{Adlercreuzia}), \textit{Lactobacillus}, \textit{Streptococcus}, \textit{Verrucomicrobia} (\textit{Akkermansia muciniphila}), \textit{Alphaproteobacteria} and \textit{Deluptrobacteria} were increased.\textsuperscript{56}

**Effects of microbiome in health and regulation of host immunity**

Normal gut microbiota perform a wide range of metabolic activities that benefit the host. Forms of vitamin K synthesised by bacteria are known as menaquinones, and are associated with cardiometabolic health in humans.\textsuperscript{57} Moreover, \textit{Bifidobacteria} and \textit{Lactobacilli} have vital roles in the synthesis of several components of vitamin B complexes.\textsuperscript{58} Healthy gut bacteria also modulate energy metabolism by increasing the serum concentrations of pyruvic acid, citric acid, fumaric acid and malic acid.\textsuperscript{59} Specific members of gut microbiota (\textit{Bacteroides}, \textit{Bifidobacterium}, \textit{Fecalibacterium} and \textit{Enterobacteria}) facilitate the fermentation of indigestible oligosaccharides resulting in the production of short chain fatty acids (SCFAs) such as acetate, propionate and butyrate. These SCFAs are present in the intestinal lumen at a total concentration of ≈ 100 mM at an approximate ratio of 6:3:1, respectively, although this is subject to carbohydrate availability, microbiota composition and intestinal transit time.\textsuperscript{60} SCFAs serve as the primary energy substrate for colonocytes and also aid in maintaining colonic epithelial integrity, regulating host energy balance, suppressing colonic inflammation and inducing apoptosis in colon cancer cells.\textsuperscript{61,62} The gut microbiota has also been shown to modulate lipid metabolism by promoting lipase activity in adipocytes.\textsuperscript{63} Targeted alterations in the gut microbiome could prove beneficial in controlling body mass, triglycerides and high-density lipoproteins.\textsuperscript{64}

Local intestinal immunity is largely regulated by resident microbiota (and/or microbial metabolites/components) and fails to develop fully in the absence of normal microbiota. This is best demonstrated in GF mice that have underdeveloped gut-associated lymphoid tissues including Peyer’s patches, isolated lymphoid follicles and mesenteric lymph nodes.\textsuperscript{65} Genesis and maturation of lymphoid follicles in mice requires stimulation by bacterial cell wall components from commensals and is mediated through nucleotide-binding oligomerization domain-containing protein 1 (NOD1) signalling.\textsuperscript{66} Establishment of normal microbiota at an early age is critical for the development of appropriate cellular immune responses, as colonisation of neonatal mice, but not adult GF mice, with conventional microbiota from wild-type mice protected the animals from pathological manifestations of IBD and asthma that were associated with the accumulation of mucosal invariant natural killer T cells. Microbiota are involved in the maintenance of innate immunity. Peptidoglycan from intestinal bacteria has been shown to regulate the steady-state cellular lifespan of neutrophils and inflammatory monocytes through NOD1 signalling.\textsuperscript{68} Commensal bacteria are commonly recognised by pathogen-sensing receptors, such as TLRs under normal conditions, which is essential in maintaining intestinal epithelial homeostasis and protects against dextran sulphate sodium-associated gut injury in mice.\textsuperscript{69} Commensal bacteria maintain the intestinal barrier in mice by selectively stimulating the release of lysozyme from secretory intestinal epithelial cells (Paneth cells) and protect the host from enteric infections through increased identification of enteric pathogens via NOD2 signalling in IBD.\textsuperscript{70} Furthermore, individual members of the intestinal microbiome can markedly alter the inflammatory state of the intestinal immune system. Murein lipoprotein from selective gut symbiotic Gram-negative bacteria are capable of inducing systemic immunoglobulin G (IgG) responses in a TLR4-dependent manner, which primarily targets bacterial antigens for removal by phagocytes and protects mice against systemic infections by \textit{Escherichia coli} and \textit{Salmonella}.\textsuperscript{71} Very recently, in an in vitro model of bone marrow-
derived macrophages, Deng et al.\textsuperscript{72} demonstrated that \textit{B. fragilis} polarises the macrophages into an proinflammatory M1 phenotype, and also enhances its phagocytic activity against pathogenic bacteria (Figure 2). Microbiota also regulate adaptive immunity. Intestinal microbiota promotes the development of CD4\textsuperscript{+} T cells, regulatory T (Treg) cells, Th1 or Th2 responses and Th17 T cells, all of which are important in the maintenance of systemic immune responses.\textsuperscript{73} Recently, it has also been shown that resident microbiota can induce high IL-21-producing CD4\textsuperscript{+} T follicular helper cells in Peyer’s patches that subsequently regulate the development of germinal centres in mice.\textsuperscript{74} The bacterial metabolites SCFAs bind specifically to the G-protein-coupled receptor 43/free fatty acid receptor 2 (GPR43/FFAR2), GPR41/FFAR3 and GPR109A, and these interactions significantly affect normal inflammatory responses. Similar to GF mice, which have negligible SCFAs, GPR43-deficient (Gpr43 \textsuperscript{-/-}) mice showed either heightened or unresolved inflammatory responses in experimental models of colitis, arthritis and asthma.\textsuperscript{75} GPR43 is expressed on cells of the distal ileum, colon, adipose tissue and immune cells, and intestinal mast cells. GPR41 is localised in the cytoplasm of enterocytes and enteronendocrine cells in human colonic mucosa. GPR41-expressing cells occur at lower levels than GPR43-expressing cells.\textsuperscript{76} Propionate-GPR41 interactions promote the development of macrophages with enhanced phagocytic activity as well as dendritic cell precursors, which migrate to the lung and possess impaired ability to differentiate naïve T cells into T\textsubscript{h}17 cells.\textsuperscript{77} Similarly, butyrate--GPR109A interactions have been shown to induce IL-10 production by colonic Treg cells in mice (Figure 2). Interestingly, a Gpr109A agonist, niacin, also suppressed colitis and colon cancer in a Niacr-knockout mice model. Moreover, microbial-derived butyrate has been shown to induce differentiation (but not survival or proliferation) of intestinal Treg cells, in both \textit{in vitro} and \textit{in vivo} models, which also ameliorated the development of colitis in Rag1\textsuperscript{-/-} mice. This promotion of Treg differentiation occurred via the activity of butyrate in inhibiting histone deacetylase, leading to enhanced histone H3 acetylation at both promoter and non-coding regions of the Foxp3 locus. In support of this, the intake of butyrylated high-amylose maize starch significantly increased IL-10-producing Treg cells in the colon.\textsuperscript{79} Microbial components also have the potential to maintain immune homeostasis in the host. Evidence is mounting in support of a ‘common mucosal response’, where the GI mucosa may regulate immune responses at distal mucosal sites (e.g., lungs), or vice versa, through the migration of preprogramed lymphoid cells and/or inflammatory mediators.\textsuperscript{80} Using animal models, it has been demonstrated that perturbation of the normal gut microbiota in inbred mice may promote fungal overgrowth in the gut, and the development of experimental asthma when challenged with fungal spores in later life (allergic airway disease), which is characterised by increased levels of in eosinophils, IgE, IL-5 and IL-13, as well as goblet cell metaplasia.\textsuperscript{81} In the respiratory tract, upper airway commensals may impart an effective antiviral immune response against influenza A virus in the lower airways through the induction of M2-macrophage-induced anti-inflammatory cytokines and inhibitory ligands.\textsuperscript{82} Furthermore, commensal neomycin-sensitive bacteria regulate protective immune responses in the lungs against influenza A virus infections by generating virus-specific CD4 and CD8 T cells through inflammasome activation and dendritic cell migration from the site of infection to lymph nodes.\textsuperscript{83} These findings clearly demonstrate a critical role for normal microbiota, as well as its metabolites, in shaping and modulating host immune responses, not only in intestinal tract but also at other sites such as the lungs.\textsuperscript{4,45} Disruption of either the composition or overall numbers of ‘normal’ microbiota (in both gut and lungs) is termed as ‘dysbiosis’, and may contribute to the development, progression, or exacerbation of various inflammatory disorders of lungs, including asthma, COPD and CF.\textsuperscript{84-87} Typically, dysbiosis is associated with the outgrowth of dominant (usually pathogenic) bacterial genera over community

![Figure 2](Image 1)

**Figure 2** Roles of commensal bacteria and/or their components/metabolites in regulation of host immunity. Commensal bacteria induce the lysozyme production by Paneth cells that reduces the colonisation of pathogenic bacteria via NOD2 sensing. Moreover, these beneficial bacteria ferment dietary fibres to produce SCFAs, which then promote the secretion of anti-inflammatory cytokines (IL-10, IL-21) by immune cells. Murein lipoprotein (MLP), a Gram-negative commensal bacterial cell wall component, can induce production of IgG, which primes macrophages and dendritic cells to remove antigens/pathogens. \textit{B. fragilis} selectively polarises macrophages into proinflammatory M1 phenotype leading to enhanced pathogen clearance/inflammation.
diversity. However, in relation to lung diseases, we do not precisely know if any of these observed microbial community changes are causal factors or result of disease, and/or then subsequently contribute to disease progression.

THE ROLE OF THE MICROBIOME IN ASTHMA
Asthma is a multifactorial disease, primarily characterised by heightened airway inflammation, associated smooth muscle hyperplasia and airway hyperreactivity.90–96 Patients are susceptible to infectious exacerbations.91 Allergic asthma develops in responses to host and environmental factors involving infections and other exposures.92–94 As the microbiota aids in the development and maturation of both innate and adaptive immunity, this potentially influences the allergic responses throughout the life of an individual, including the development of allergic asthma.94–96 Several studies have observed a positive association between childhood antibiotic exposure, which disrupts the normal microbiome, and risk of early-onset childhood asthma.97 The role of the microbiome appears to relate directly to the type of microbial exposure as opposed to the total microbial load. Indeed, neither personal nor home cleanliness were associated with a risk for asthma and allergies, but exposure to specific microbial markers in the environment, such as muramic acid and endotoxin, correlated with asthma prevalence (odds ratio (OR): 0.59; 95% confidence interval (CI): 0.39–0.90) and allergic sensitisation (OR: 0.73; 95% CI: 0.56–0.96) in school-age children.98

The diversity of nasopharyngeal microbiota has a fundamental role in determining the host susceptibility to febrile lower respiratory infections and the development of asthma later in life.99 In particular, colonisation of the hypopharyngeal region of 1-month-old infants (n = 321) with Moraxella catarrhalis, Haemophilus influenzae or Streptococcus pneumoniae was associated with a significantly increased risk for childhood asthma.100 Respiratory H. influenzae, Chlamydia and viral infections are linked to severe asthma.90,101–103 In human adults, the composition of the lung microbiome in asthmatics differs significantly from healthy controls,84 which seems to regulate proinflammatory immune responses. Several studies have reported greater abundance of Proteobacteria in the lower airway secretions of asthmatics compared with healthy individuals,94,104 which was also associated with T17-associated gene expression.105 Specific pulmonary bacterial communities have been associated with clinical characteristics (e.g., sputum total leukocyte levels, reduced quality of life) in severe asthma (dominated by Actinobacteria) and differs from both healthy individuals and patients with mild-to-moderate asthma.105 Interestingly, asthmatics who displayed improved bronchial reactivity after 6 weeks of macrolide antibiotic (clarithromycin) treatment had higher baseline bacterial diversity,106 potentially implicating the resident microbiota in the outcome of therapeutic interventions. In addition to bacterial communities, the analysis of induced sputum revealed that 90 fungal species were more abundant in asthmatics, whereas 46 were more abundant in the control subjects.107 In particular, members of genera Aspergillus and Penicillium were significantly associated with impaired postbronchodilator reduced expiratory volume in 1 s in asthmatics.108 Mouse models have been developed that replicate features of acute, chronic, mild-to-moderate and severe steroid-resistant asthma.109,110–112 Such models have been used to confirm this role for the respiratory microbiota in allergic asthma, as increased infiltration of lymphocytes and eosinophils occurred following ovalbumin administration in GF compared with SPF mice, which could be reversed with recolonising GF mice with normal microflora113 (phenotype-specific).

In addition to the modulation of immunity by the lung microbiome, perturbations in GI microbiota, such as through antibiotic use and poor diet, may disrupt mucosal tolerance. A recent Finnish study showed that the use of macrolides in early life was associated with long-term microbial dysbiosis (depletion of Actinobacteria, increased Bacteroidetes and Proteobacteria), and significantly increased asthma risk and antibiotic-associated weight gain in 2–7-year-old children.114 A mouse model of antibiotic use in early life demonstrated significant changes in gut microbiome composition (both richness and Shannon evenness) that was dependent on the number of courses and class of antibiotic used, resulting in weight gain.115 Similarly, vancomycin-treated neonatal mice exhibited markedly altered gut microbiota and heightened allergic asthma characterised by significant increases in bronchoalveolar lavage fluid eosinophils, serum ovalbumin-specific IgE levels and airway hyperresponsiveness compared with control mice.116 Even in the absence of antibiotics, subtle differences in the GI microbiota in early life can affect asthma risk. Data from Canadian Healthy Infant Longitudinal Development (CHILD) Study (n = 319) demonstrated that gut microbial dysbiosis during the first 3 months of life predisposed infants to a relatively high risk of asthma, which was associated with significant decreases in bacterial genera Faecalibacterium, Lachnospira, Veillonella and Rothia as well as reduced faecal acetate levels. GF mice inoculated with faeces lacking these taxa exhibited airway inflammation and pathology in their adult progeny. This was improved in mice inoculated with the same faeces supplemented with the specific bacterial taxa, demonstrating a beneficial role for these bacterial taxa in asthma prevention.117

Furthermore, pregnant mice fed with high-fibre/acetate diet protected the offspring against the development of allergic airway disease, possibly via histone deacetylase 9 inhibition and promoting highly suppressive Treg cells involving acetylation at the Foxp3 promoter region.118

Apart from infancy, the changing microbiota throughout life may influence allergic asthma. Vital et al.119 found that aged mice (9–10 months) that were sensitised and challenged with house dust mite exhibited greater allergic airway responses compared with young similar treated mice (6–8 weeks). Notably, age-related gut microbiota alterations in old mice (decrease in Bacteroidetes:Firmicutes ratio) resemble those in mice challenged with house dust mite. In addition, intestinal microbial dysbiosis was significantly associated with elevated bronchoalveolar lavage fluid IL-17A and increased Th17 cells in the spleen in aged mice, whereas serum IL-17A levels were increased in both groups. This study suggests important links between age-associated gut microbial dysbiosis and allergic airway responses. Moreover, interestingly, pulmonary sensitization with house dust mite may drive alterations in gut microbiome through priming Th17 regulatory cells.

THE ROLE OF THE MICROBIOME IN COPD
COPD is a multicomponent disease that involves airway inflammation, mucociliary dysfunction and lung structural changes, which are observed in varying degree of severities in COPD patients, and contribute to airflow obstruction and breathing difficulties.120–122 The structural and airway changes in COPD patients include small airway fibrosis and emphysema, whereas the large airways demonstrate epithelial goblet cell hyperplasia, epithelial squamous metaplasia and submucosal gland hyperplasia. Emphysema develops usually after a decade and only in a subset of patients.123 Tobacco smoking remains the principal causal factor worldwide, especially in developed countries. In addition to cigarette smoke, exposure to biomass
fuel smoke and air pollution contribute significantly in disease prevalence in low- and middle-income countries.\textsuperscript{124,125}

The clinical course of COPD is complicated by frequent episodes of acute exacerbations, which primarily involves microbial and viral infections.\textsuperscript{91,126,127} In the past two decades, our understanding of the pathogenesis of airway infections has increased substantially. The most common ‘colonisers’ in the stable state of COPD are non-typeable \textit{H. influenzae} (\textasciitilde60\%), \textit{M. catarrhalis} (\textasciitilde48\%) and \textit{S. pneumoniae} (\textasciitilde28\%).\textsuperscript{128} Moreover, bacterial colonisation of the respiratory tract in COPD patients is believed to be dynamic, as the bacterial flora frequently changes in terms of both strains and species, although the above-mentioned bacteria remain prominent.\textsuperscript{129} These bacterial pathogens undoubtedly worsen a patient’s health over a long period of time and may be a major driver of airway luminal inflammation and oxidative stress,\textsuperscript{128,130-133} as well as increased daily symptoms in COPD patients.\textsuperscript{134} Indeed, COPD patients chronically colonised with \textit{H. influenzae} during stable phase showed increased airway inflammation and reduced lung volumes when compared with non-chronically colonised patients.\textsuperscript{135}

The influence of cigarette smoke on the microbiome and the role of the microbiome in COPD are relatively new paradigms with limited data.\textsuperscript{4,145} However, both of these issues could be relevant in understanding disease development, progression and exacerbations. Results from a multicentre cohort study (\textit{n} = 64), based on modern culture-independent techniques such as quantitative reverse transcription PCR (using 16S rRNA) show that the oropharyngeal microbiome (oral wash) differed in non-smokers compared with smokers, but no difference was found in lung microbial communities using bronchoalveolar lavage.\textsuperscript{136} In contrast, the microbial communities in the lungs of COPD patients differ significantly from both healthy smokers and non-smokers, primarily due to an enrichment of some taxa including \textit{Firmicutes} (e.g., \textit{Lactobacillus}, \textit{Streptococcus}) and \textit{Proteobacteria} (e.g., \textit{Burkholderia}, \textit{Campylobacter}).\textsuperscript{32,33,137,138}

Studies of the COPD microbiome have also shown significant biogeographical and temporal variations in microbial diversity and relative abundance.\textsuperscript{32,33,138} In a healthy individual, spatial and temporal variation in microbiota composition is significantly less than variation across individuals and is primarily influenced by microbial immigration and elimination, whereas in disease microbial communities are more likely to be affected by local growth conditions.\textsuperscript{26} In particular, the decline in both the diversity and richness in the respiratory microbiome is shown to be associated with greater emphysema and increased immune cell infiltration in COPD patients.\textsuperscript{33} Moreover, a recent study by Wang \textit{et al}.\textsuperscript{139} showed different phenotypic patterns in COPD exacerbations (e.g., bacterial or eosinophilic), which were associated with distinct lung microbiome profiles at both phylum and genus levels. In patients exhibiting bacterial exacerbations, the microbiome was dominated by the phyla \textit{Proteobacteria} (mainly \textit{Haemophilus} spp.), whereas \textit{Firmicutes} dominated eosinophilic exacerbations. Thus, changes in the lung microbiota composition may be associated with acute exacerbations and could potentially shape host inflammatory responses (especially IL-8), at least in some individuals.

Mouse models have been developed that replicate features of COPD, including exacerbations, in a short time frame and can be used in cause and effect and mechanism studies.\textsuperscript{110,121,122,126,140-144} Several mechanistic studies in animals have explored the modulation of lung immunity by lung microbes. One of the first showed a causal relationship between the bacterial microbiome, inflammation and IL-17A-mediated lymphoid follicle formation.\textsuperscript{145} In a lipopolysaccharide/elastase-challenged mouse model of COPD, Yadava \textit{et al}.\textsuperscript{145} showed that treated mice had decreased microbiota richness and diversity compared with SPF mice, with an increased representation of the genera \textit{Pseudomonas} and \textit{Lactobacillus} and a reduction in \textit{Prevotella}. The authors also observed increased inflammation (lymphoid follicle formation), extensive lung damage as well as increased production of antibodies and IL-17A in treated mice. Interestingly, GF mice exhibited reduced inflammatory cells in the airways, indicating that microbial factors modulate lung inflammatory responses.\textsuperscript{145} In addition, intranasal administration of bronchoalveolar lavage fluid from lipopolysaccharide/elastase-treated mice, but not from phosphate-buffered saline-treated mice, resulted in an increase in IL-17A-producing cells in the lungs of both GF mice and antibiotic-treated mice.\textsuperscript{145} Besides inflammation, lung microbiome may also affect lung architecture, which could significantly affect both pulmonary function and airflow obstruction. Yun \textit{et al}.\textsuperscript{146} reported metabolically active lung microbiota in both SPF- and wild-type outbred mice, but not in GF mice. Although the overall microbiome composition across these mice was similar at the phylum and family level, species richness was significantly different between those housed in SPF and non-SPF facilities. The authors also found a positive correlation between higher bacterial abundance in non-SPF mice and increased number and smaller size alveoli.\textsuperscript{146}

The GI microbiome has not been characterised in COPD patients; however, there is evidence of gut bacterial dysbiosis in response to cigarette smoke in both humans and mice. Compared with non-smoking Crohn’s disease patients, gut microbial gene richness, genus and species diversity were reduced in smoking patients, with lower relative abundance of the genera \textit{Collinsella}, \textit{Enterorhabdus} and \textit{Gordonibacter}, and of \textit{Faecalibacterium prausnitzii}.\textsuperscript{147} Moreover, significant alterations in microbiota composition has been reported in healthy smokers, which reverses upon smoking cessation, with marked increases in overall microbial diversity and an increase in the phyla \textit{Firmicutes} and \textit{Actinobacteria}, as well as a lower proportion of \textit{Bacteroidetes} and \textit{Proteobacteria}, compared with continuing smokers and non-smokers.\textsuperscript{148} Colonial bacterial dysbiosis was also reported in mice chronically (24 weeks) exposed to cigarette smoke, with increases in \textit{Lachnospiraceae} sp.\textsuperscript{149}

Increased levels of reactive oxygen species likely drives pathophysiology of COPD.\textsuperscript{150} Bacterial activation of NOD-like receptors in the GI tract enhances production of reactive oxygen species in alveolar macrophages, potentially implicating the GI microbiome in oxidative stress and inflammation in COPD.\textsuperscript{151} There is evidence for the beneficial use of probiotic bacterial strains to modulate lung immune responses in COPD patients. Phagocytosis of \textit{Lactobacillus rhamnosus} and \textit{Bifidobacterium breve} by human macrophages in vitro resulted in the suppression of cigarette smoke-induced nuclear factor-kB activation and associated inflammation.\textsuperscript{152} In addition, daily intake of \textit{Lactobacillus casei Shirota} increased the cytotoxic activity of natural killer cells as well as CD16+ cells in current smokers.\textsuperscript{153} Respiratory syncytial virus infection can lead to significant airspace enlargement and fibrosis in mice exposed to cigarette smoke, as well as heightened disease severity in mice.\textsuperscript{154} Notably, administration of \textit{L. rhamnosus} before respiratory syncytial virus infection in mice resulted in elevated antiviral responses via TLR3/RIG-I activation.\textsuperscript{155} Although the role of microbiome in COPD needs to be further investigated, early studies have suggested an association between both lung and gut microbiota and the outcomes of disease.

**THE ROLE OF THE MICROBIOME IN CF**

CF is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein that affects various
In other studies, Hoen et al. demonstrated that the administration of streptomycin significantly reduced gut bacterial overgrowth compared with wild-type mice and ameliorated airway hyperresponsiveness. Cftr mutants had reduced lymphocytes in lymph nodes, which could be restored with streptomycin treatment, whereas γδ T cells were not changed in Cftrtm1UNC mice, they were reduced by the same treatment. This study further strengthens the notion that gut microbiota indeed influences lung inflammatory responses in CF.

**CONCLUSIONS AND FUTURE DIRECTIONS**

Evidence suggests that certain microbes have pivotal roles in the development of healthy immune responses, and microbial dysbiosis can contribute to chronic inflammatory lung diseases such as asthma, COPD and CF. The cross-talk between mucosal barriers, such as occurs in gut–lung cross-talk, is considered to be mediated by both resident microbes and patrolling immune cells, but this remains to be fully elucidated. Currently, available treatments for major non-communicable lung diseases only focus on alleviating symptoms with poor applicability to completely prevent and/or treat the diseases. A better understanding of microbiome-driven pathophysiology and inflammation, in conjunction with the interaction of major risk factors for chronic lung disease such as host genetics and cigarette smoking, would aid in optimising current treatments and in managing these chronic lung conditions (Figure 3). Furthermore, by improving our understanding of the role of microbiomes in these diseases, novel therapeutic strategies may be developed. The effects of current therapeutics on overall microbiome, and consequently on the disease severity/progression, remains largely unknown and needs to be properly understood to realise the full impact of these treatments. Modification of the microbiome through diet, probiotics, faecal or selected bacterial transfers may supplement currently available therapies in the management of chronic lung diseases (Figure 3).
treatments or be effective treatments in their own right, but further research into such alternatives is required.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
PMH is supported by fellowships and grants from the National Health and Medical Research Council (NHMRC) of Australia and the Brawn Fellowship, Faculty of Health and Medicine, The University of Newcastle, NSW, Australia, and the Rainbow Foundation. We thank F Thomson and M Thomson for their continued support.

1 WHO. the Top 10 Causes of Death. World Health Organization; Geneva. 2014.
2 Australian Bureau of Statistics. National Health Survey: First Results, 2014-15. ABS: Canberra. 2015; 68: 0.7-10: 1864; 635; 104.
3 O'Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol 2016; 196: 4839–4847.
4 Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55–63.
5 Nguyen LD, Viscogliosi E, Delahaye L. The lung microbiome: an emerging field of the human respiratory microbiome. Front Microbiol 2015; 6: 1–9.
6 Cadwell K. The virome in host health and disease. Immunity 2015; 42: 805–813.
7 UrSELL I, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev 2012; 70: 534–544.
8 Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Curr Opin Microbiol 2013; 16: 825–832.
9 O'Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol 2016; 196: 4839–4847.
10 Slotta JD. The virome in host health and disease. Immunity 2015; 42: 805–813.
11 O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol 2016; 196: 4839–4847.
12 Schloos PG. The effects of alignment quality, distance calculation method, sequence filtering, and region on the analysis of 16S rRNA gene-based studies. PLoS Comput Biol 2010; 6: e1000844.
13 Lindahl B, Nilsen RH, Tadesuo L, Abarenkov K, Carlsen T, Kjoller R et al. Fungal community analysis by high-throughput sequencing of amplified markers—a user’s guide. New Phytol 2013; 199: 288–299.
14 Anderson IC, Campbell CD, Prosser JI. Potential bias of fungal 18S rDNA and internal transcribed spacer polymerase chain reaction primers for estimating fungal biodiversity in soil. Environ Microbiol 2003; 5: 36–47.
15 Casjens SR. Comparative genomics and evolution of the tailed-bacteriophages. Nat Rev Micro 2003; 5: 51–54.
16 Metcalf J. The virome in host health and disease. Immunity 2015; 42: 805–813.
17 Martin R, Makino H, Getuneyre A, Ben-Amor K, Roelofs M, Ishikawa E et al. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. PLoS ONE 2016; 11: e0158496.
18 Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C et al. A human gut microbiome dataset with comprehensive metadata. Environ Microbiol 2010; 12: 338–350.
19 Tatusova T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222–227.
20 Chaversen R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol 2015; 16: 191.
21 Dietrich RR, Diakos B, Blaser MJ. The human microbiome: at the interface of health and disease. Curr Opin Microbiol 2018; 45: 451–458.
22 Molitor M, Nilsen RH, Tadesuo L, Abarenkov K, Carlsen T, Kjoller R et al. Fungal community analysis by high-throughput sequencing of amplified markers—a user’s guide. New Phytol 2013; 199: 288–299.
23 Anderson IC, Campbell CD, Prosser JI. Potential bias of fungal 18S rDNA and internal transcribed spacer polymerase chain reaction primers for estimating fungal biodiversity in soil. Environ Microbiol 2003; 5: 36–47.
24 Metcalf J. The virome in host health and disease. Immunity 2015; 42: 805–813.
25 Martin R, Makino H, Getuneyre A, Ben-Amor K, Roelofs M, Ishikawa E et al. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. PLoS ONE 2016; 11: e0158496.
26 Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C et al. A human gut microbiome dataset with comprehensive metadata. Environ Microbiol 2010; 12: 338–350.
27 Tatusova T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222–227.
28 Chaversen R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol 2015; 16: 191.
29 Dietrich RR, Diakos B, Blaser MJ. The human microbiome: at the interface of health and disease. Curr Opin Microbiol 2018; 45: 451–458.
Montagudo-Mera A, Arthur J, Jobin C, Keki T, Bruno-Barcena J, Azcarate-Peril M. High purify galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome. Benef Microbes 2016; 7: 247–264.

Caro-T, R Tremaroli V, Kovatcheva-Datchary P, Cani Patrice D, Backhed F. Crossstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metabol 2015; 22: 658–668.

Kari JP, Fu X, Wang X, Zhao Y, Shen J, Zhang C et al. Changes in fecal vitamin K composition are associated with the gut microbiota. The FASEB Journal 2015; 29: 1451–1457.

LeBlanc BG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 2013; 24: 160–168.

Velagapudi VR, Hezaveh R, Reisgad CS, Gopachalayury P, Yetukuri L, Islam S et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2015: 51: 1101–1112.

Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Nutr Rev 2003; 61: 67–72.

Suzuki Y, Yoshida S, Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 2008; 100: 297–305.

Suzuki Y, Zhang Y, Vazquez N, Prasad PD, Martin PM, Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr Opin Pharmacol 2013; 13: 869–874.

Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 2014; 111: 7421–7426.

Fu J, Border MJ, Cenit MC, Tsigchelea EF, Maatman A, Dekens JAM et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res 2015; 117: 817–824.

Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313–323.

Bouzakri D, Brezillon C, Berard M, Werts C, Vanona R, Boneca IG et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008; 456: 507–510.

Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336: 489–493.

Herriott CB, Roche AM, Tamashiro E, Clarke TB, Bailey AG, Laughlin A et al. Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at steady state. Blood 2016; 127: 2460–2471.

Rakoff-Nahoum S, Paglino J, Elinav E, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229–241.

Zhang Q, Pan Y, Yan R, Zeng B, Wang H, Zhang X et al. Commensal bacteria direct selective cargo sorting to promote symbiosis. Nat Immunol 2015; 16: 918–926.

Zeng MY, Cisalpino D, Vanadaranja S, Sellman J, Warren HS, Casalho M et al. Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity 2016; 44: 647–658.

Deng H, Li Z, Tan Y, Guo Z, Liu Y, Wang Y, Yuan Y et al. A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages. Sci Rep 2016; 6: 29041.

Samuelson DR, Welsh DA, Sheltito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol 2015; 6.

Jones L, Ho WQ, Ying S, Ramakrishna L, Sinivasan KG, Yurieva M et al. A subpopulation of high IL-21-producing CD4+ T cells in Peyer's Patches is induced by the intestinal microbiota. Blood 2015; 126: 1921–1929.

Maslowski KM, Vieira AT, Murat D, Atef H et al. The FAE2 receptor of L. casei regulates germinal centers. Blood 2016; 127: 2460–2472.

Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M et al. Expression of short-chain fatty acid receptor GPR43 in the human colon. Biomed Res 2009; 30: 149–156.

Tormpette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngorn-Bru C et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014; 20: 159–166.

Singh N, Gurav A, Sivaprasakam S, Brady E, Padia R, Shi H et al. Activation of GPR109A receptor in naif and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014; 40: 128–139.

Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al. Commensal microbiota-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 14: 446–450.

Czerkinsky C, Prince SJ, Michalek SM, Jackson S, Russell MW, Moldoveanu Z et al. lgG antibody-producing cells in peripheral blood after antigen injection: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci USA 1987; 84: 2449–2453.

Novell MC, Nogge RM, Toews GB, Huffnagle GB. Role of antibodies and fungal microbiota in driving pulmonary allergic responses. Infect Immun 2004; 72: 4996–5003.

Wang J, Fan J, Sun R, Gao X, Wei H, Li LJ et al. Bacterial colonization damages influenza-mediated acute lung injury via induction of M2 alveolar macrophages. Nat Comm 2013; 4: 241.
110 Liu G, Cooley MA, Jamnicki AG, Hsu AC, Nair PM, Haw TJ et al. Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases. *JCI Insight* 2016; 1.

111 Thorburn AN, Foster GS, Gibson PG, Hansbro PM. Components of Streptococcus pneumoniae suppress allergic airway disease and NKT cells by inducing regulatory T cells. *Immunology* 2015; 146:411-420.

112 Preston JA, Essilfe AT, Horvat JC, Wade MA, Beagley KW, Gibson PG et al. Inhibition of allergic airways by immunomodulatory therapy with whole killed Streptococcus pneumoniae. *Vaccine* 2007; 25: 8154-8162.

113 Herbst T, Tschiedel C, Orzack T, Cypert C, Yadav A, Burri K, C投资者 J et al. Dysregulation of allergic airway inflammation in the absence of microbial colonization. *Am J Respir Crit Care Med* 2011; 184: 198-205.

114 Korpela K, Salonen A, Virts LJ, Kekkonen RA, Forslund K, Bork P et al. Intestinal microbiota is required for effective antigen-specific immune response in Finnish pre-school children. *Nat Commun* 2016; 7: 10410.

115 Nobel YR, Cox LM, Kirking FF, Bokulich NA, Yarnantis S, Teitler I et al. Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. *Nat Commun* 2015; 6: 7486.

116 Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M et al. Early infancy antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. *EMBO Rep* 2012; 13: 440-447.

117 Arriga MC, Slemmert LT, Dimitriu PA, Thorsen L, Russell S, Yurol-Doubst S et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med* 2015; 7: 307ra152.

118 Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ et al. Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable *Haemophilus influenzae* during stable disease. *Respirology* 2015; e1004549.

119 Hsu AC, Parsons K, Moheimani F, Knight DA, Hansbro PM, Fujita T et al. The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model. *Br J Pharmacol* 2016; 173: 3161-3175.

120 Hansbro PM, Hamilton MJ, Fricker MJ, Gellatly SL, Jamnicki AG, Zheng D et al. Importance of mast cell P33/ transmembrane tryptase/tryptase-gamma in lung function and experimental chronic obstructive pulmonary disease and colitis. *J Biol Chem* 2014; 289: 18214-18227.

121 Fricker M, Deane A, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. *Mucosal Immunol* 2012; 5: 7-18.

122 Fricker M, Deane A, Hansbro PM. Animal models of chronic obstructive pulmonary disease. *Expert Opin Drug Discov* 2014; 9: 629-645.

123 Jones B, Donovan C, Liu G, Gomez HM, Chimnarska V, Harrison CL et al. Animal models of COPD: What do they tell us? *Respir Med* 2016; 22: 21-32.

124 Sohail SS, Ward C, Danial W, Wood-Baker R, Walters EH. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. *Expert Rev Respir Med* 2013; 7: 275-288.

125 From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Available at: http://goldcopd.org (accessed on 22/11/2016).

126 Hirata JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D et al. Bronchial microbiome of severe COPD patients colonised by *Pseudomonas aeruginosa*. *Am J Respir Cell Mol Biol* 2015; 52: 96-105.

127 Hsu AC, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ et al. Targeting P13K-p110alpha suppresses influenza virus infection in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 191: 1021-1023.

128 Hsu AC, Parsons K, Moheimani F, Knight DA, Hansbro PM, Fujita T et al. Impaired antiviral stress granule and IFN-beta enhanceosome formation enhances susceptibility to tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease. *Mucosal Immunol* 2016; 9: 859-872.

129 Jamnicki AG, Schilter H, Liu G, Wheelock K, Essilfe AT, Foot JS et al. The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model. *Br J Pharmacol* 2016; 173: 3161-3175.

130 Hansbro PM, Hamilton MJ, Fricker MJ, Gellatly SL, Jamnicki AG, Zheng D et al. Importance of mast cell P33/ transmembrane tryptase/tryptase-gamma in lung function and experimental chronic obstructive pulmonary disease and colitis. *J Biol Chem* 2014; 289: 18214-18227.

131 Singanayagam A, Gianviti N, Walton RN, Anisecenko J, Pearson RM, Pirinkton JN et al. A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD. *Clin Sci (Lond)* 2015; 129: 245-258.

132 Yadava K, Patilmarini C, Schildhier AK, Trompette A, Golwitzer ES, Sallam O et al. Microbiota promotes chronic obstructive pulmonary disease in obese mice. *PLoS ONE* 2015; 10: e0128746.

133 Opstelten JL, Plaisais J, van Mil SW, Achouri E, Pichaud M, Sieriens PD et al. Gut microbial diversity is reduced in smokers with Crohn's disease. *Inflamm Bowel Dis* 2016; 22: 2070-2077.

134 Badermann L, Zelt J, Mrwini J, Sutter-Minder E, Rehman A, Ott SJ et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. *PLOS ONE* 2013; 8: e59260.

135 Aliass L, Kerkof HM, Verschuere S, Bracke KR, De Smet R, Laukens D et al. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. *Environ Microb* 2016; 18: 1352-1363.

136 Becker W, Singh R, Wedzicha J, Barnes P, Donnelly L. Elevated mitochondrial reactive oxygen species in COPD macrophages at exacerbation. *Eur Respir J* 2015; 46: PA387.

137 Clarke TB. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. *Infect Immun* 2014; 82: 4596-4606.

138 Mortaz E, Adcock IM, Ricciardolo FL, Varahram M, Jamaati H, Velayati AA et al. Anti-inflammatory effects of *Lactobacillus rhamnosus* and *Bifidobacterium breve* on cigarette smoke activated human macrophages. *PLOS ONE* 2015; 10: e0136455.

139 Kato Y, Casalino P, Bellante V, Tarantelli D, Di Nicola M, Ferrella S et al. Daily intake of *Lactobacillus casei* shirota increases natural killer cell activity in smokers. *Br J Nutr* 2012; 108: 308-317.

140 Forony RF, Dabo AJ, Taggart CC, Weldon S, Geraghty P. Respiratory viral infection enhances cigarette smoke induced COPD in mice. *PLOS One* 2014; 9: e95067.

141 Tomaseda Y, Chiba E, Zelaya H, Takahashi T, Tsukuida K et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory viral infection. *BMC Immunol* 2013; 14: 40.

142 Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989; 245: 1066-1073.

143 Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. *eLife* 2012; 1: e00420.

144 Mirkovic M, Murray MA, Lavelle GM, Molloky K, Aziz AA, Gunaratnam C et al. The role of short-chain fatty acids, produced by anaerobic bacteria, in the cystic fibrosis airway. *Am J Respir Crit Care Med* 2015; 192: 1314-1324.

145 Gharbian P, Sathakumar P, Hu Q, Djadeu P, Wolever TM, Palanjian N et al. Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. *Eur Respir J* 2015; 46: 1033-1045.

146 Hoen AG, Li J, Moulton LA, O'Toole GA, Housman ML, Koestler DC et al. Associations between gut microbial composition and inflammatory markers in cystic fibrosis: *Am J Respir Crit Care Med* 2015; 167: 138-147 e131-e133.

147 Smyth RL, Croft NM, O'Hare U, Marshall TG, Ferguson A. Intestinal inflammation in cystic fibrosis. *Arch Dis Child* 2000; 82: 394-399.

148 Dhalwal J, Leach S, Katz T, Nahid L, Pang T, Lee JM et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 2015; 60: 521-526.
163 Nielsen S, Needham B, Leach ST, Day AS, Jaffe A, Thomas T et al. Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep 2016; 6.

164 Al-momani H, Perry A, Stewart CJ, Jones R, Krishnan A, Robertson AG et al. Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients. Sci Rep 2016; 6.

165 Schippa S, Iebba V, Santangelo F, Gagliardi A, De Biase RV, Starnato A et al. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients. PLoS ONE 2013; 8: e61176.

166 Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R et al. Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis. Sci Rep 2016; 6: 22493.

167 Bazett M, Bergeron ME, Haston CK. Streptomycin treatment alters the intestinal microbiome, pulmonary T cell profile and airway hyperresponsiveness in a cystic fibrosis mouse model. Sci Rep 2016; 6.